Crossject S.A (ALCJ) | Financial Analysis & Statements
Crossject S.A. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
30.4M
Total Liabilities
35.3M
Shareholders Equity
-4.9M
Cash Flow Metrics
Revenue & Profitability Trend
Crossject S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 145.0K | 954.0K | 912.0K |
| Cost of Goods Sold | 9.7M | 9.2M | 6.3M | 2.2M | 1.3M |
| Gross Profit | -9.7M | -9.2M | -6.1M | -1.2M | -390.0K |
| Gross Margin % | 0.0% | 0.0% | -4,231.0% | -126.4% | -42.8% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | - | - | - | - | - |
| Other Operating Expenses | 1.5M | 569.0K | -394.0K | 1.3M | 969.0K |
| Total Operating Expenses | 1.5M | 569.0K | -394.0K | 1.3M | 969.0K |
| Operating Income | -11.6M | -13.0M | -11.6M | -13.3M | -11.8M |
| Operating Margin % | 0.0% | 0.0% | -7,996.6% | -1,392.9% | -1,296.4% |
| Non-Operating Items | |||||
| Interest Income | - | 53.0K | 36.0K | - | 19.0K |
| Interest Expense | - | 1.1M | 737.0K | - | 845.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -13.2M | -15.6M | -11.5M | -13.4M | -12.6M |
| Income Tax | -2.8M | -2.8M | -2.9M | -2.2M | -1.8M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -10.4M | -12.8M | -8.6M | -11.2M | -10.8M |
| Net Margin % | 0.0% | 0.0% | -5,957.9% | -1,169.5% | -1,184.9% |
| Key Metrics | |||||
| EBITDA | -5.9M | -6.5M | -7.1M | -7.4M | -6.8M |
| EPS (Basic) | - | €-0.28 | €-0.23 | €-0.29 | €-0.40 |
| EPS (Diluted) | - | €-0.28 | €-0.23 | €-0.29 | €-0.40 |
| Basic Shares Outstanding | - | 46201643 | 37413293 | 37491707 | 26737467 |
| Diluted Shares Outstanding | - | 46201643 | 37413293 | 37491707 | 26737467 |
Income Statement Trend
Crossject S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 5.1M | 7.0M | 2.3M | 7.8M | 10.0M |
| Short-term Investments | - | - | - | - | 154.0K |
| Accounts Receivable | - | 1.8M | 4.8M | 3.5M | 2.0M |
| Inventory | 3.5M | 3.4M | 3.1M | 2.0M | 1.4M |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 15.4M | 15.9M | 10.7M | 13.8M | 14.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.4M | 10.9M | 2.8M | 5.2M | 6.1M |
| Goodwill | 8.1M | 9.6M | 10.7M | 10.7M | 9.1M |
| Intangible Assets | 8.1M | 9.6M | 10.7M | 10.7M | 9.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 15.0M | 15.7M | 18.0M | 19.0M | 17.1M |
| Total Assets | 30.4M | 31.6M | 28.6M | 32.9M | 31.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 4.4M | 4.6M | 4.3M | 3.5M | 2.0M |
| Short-term Debt | - | 3.3M | - | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | 1.0K | - | 8.0K | 66.0K |
| Total Current Liabilities | 6.6M | 10.2M | 7.1M | 5.3M | 3.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 19.8M | 17.7M | 18.9M | 14.1M | 25.6M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 7.3M | 5.4M | 7.1M | 9.3M | 7.5M |
| Total Non-Current Liabilities | 28.7M | 24.1M | 26.8M | 24.8M | 33.9M |
| Total Liabilities | 35.3M | 34.2M | 33.9M | 30.2M | 37.0M |
| Equity | |||||
| Common Stock | 5.2M | 4.6M | 3.7M | 3.7M | 2.6M |
| Retained Earnings | -18.8M | -15.4M | -10.4M | -19.9M | -14.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -4.9M | -2.7M | -5.3M | 2.7M | -5.5M |
| Key Metrics | |||||
| Total Debt | 19.8M | 21.1M | 18.9M | 14.1M | 25.6M |
| Working Capital | 8.9M | 5.7M | 3.5M | 8.5M | 11.3M |
Balance Sheet Composition
Crossject S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -10.4M | -12.8M | -8.6M | -11.2M | -10.8M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 0 | 0 | 0 | 0 | 0 |
| Operating Cash Flow | -10.3M | -13.1M | -8.7M | -11.2M | -10.8M |
| Investing Activities | |||||
| Capital Expenditures | -4.5M | -3.4M | -2.6M | -6.8M | -6.7M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -4.5M | -3.4M | -2.6M | -6.8M | -6.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 8.2M | 6.7M | 8.1M | 4.1M | 20.9M |
| Debt Repayment | -3.5M | -3.4M | -5.1M | -1.5M | -7.1M |
| Financing Cash Flow | 8.9M | 16.1M | 3.4M | 9.6M | 14.5M |
| Free Cash Flow | -10.8M | -11.5M | -12.6M | -11.9M | -12.8M |
| Net Change in Cash | -6.0M | -372.7K | -7.9M | -8.3M | -3.0M |
Cash Flow Trend
Crossject S.A Key Financial Ratios
Valuation Ratios
Forward P/E
3.48
Price to Sales
41.73
PEG Ratio
3.48
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-630.31%
Return on Equity
212.74%
Return on Assets
-23.40%
Financial Health
Current Ratio
2.57
Debt to Equity
-4.61
Beta
0.52
Per Share Data
EPS (TTM)
€-0.20
Book Value per Share
€-0.02
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALCJ | 105.6M | - | - | 212.74% | 0.00% | -4.61 |
| Sartorius Stedim | 15.8B | 59.45 | 3.86 | 6.59% | 8.98% | 63.11 |
| Visiomed Group SA | 52.8M | 59.67 | - | 3.64% | 45.95% | 0.32 |
| Spineway S.A | 5.8M | 16.20 | 0.25 | -9.46% | -17.47% | 6.63 |
| Bonyf N.V | 2.5M | - | 5.72 | -32.61% | 8.02% | 0.00 |
Financial data is updated regularly. All figures are in the company's reporting currency.